These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

421 related articles for article (PubMed ID: 29163851)

  • 1. Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity.
    Mittica G; Ghisoni E; Giannone G; Aglietta M; Genta S; Valabrega G
    Oncotarget; 2017 Oct; 8(52):90532-90544. PubMed ID: 29163851
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor genotype and immune microenvironment in POLE-ultramutated and MSI-hypermutated Endometrial Cancers: New candidates for checkpoint blockade immunotherapy?
    Gargiulo P; Della Pepa C; Berardi S; Califano D; Scala S; Buonaguro L; Ciliberto G; Brauchli P; Pignata S
    Cancer Treat Rev; 2016 Jul; 48():61-8. PubMed ID: 27362548
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association of Polymerase e-Mutated and Microsatellite-Instable Endometrial Cancers With Neoantigen Load, Number of Tumor-Infiltrating Lymphocytes, and Expression of PD-1 and PD-L1.
    Howitt BE; Shukla SA; Sholl LM; Ritterhouse LL; Watkins JC; Rodig S; Stover E; Strickland KC; D'Andrea AD; Wu CJ; Matulonis UA; Konstantinopoulos PA
    JAMA Oncol; 2015 Dec; 1(9):1319-23. PubMed ID: 26181000
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune profiling of microsatellite instability-high and polymerase ε (
    Wang C; Gong J; Tu TY; Lee PP; Fakih M
    J Gastrointest Oncol; 2018 Jun; 9(3):404-415. PubMed ID: 29998005
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Application and clinical significance of TCGA molecular classification in endometrial cancer].
    Zhao LY; Dai YB; Li LW; Wang ZQ; Wang JL
    Zhonghua Fu Chan Ke Za Zhi; 2021 Oct; 56(10):697-704. PubMed ID: 34823319
    [No Abstract]   [Full Text] [Related]  

  • 6. Immunological profiling of molecularly classified high-risk endometrial cancers identifies
    Eggink FA; Van Gool IC; Leary A; Pollock PM; Crosbie EJ; Mileshkin L; Jordanova ES; Adam J; Freeman-Mills L; Church DN; Creutzberg CL; De Bruyn M; Nijman HW; Bosse T
    Oncoimmunology; 2017; 6(2):e1264565. PubMed ID: 28344870
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immunotherapy for endometrial cancer.
    Wada M; Yamagami W
    Int J Clin Oncol; 2024 Jun; ():. PubMed ID: 38913219
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Immune checkpoint inhibitors for recurrent endometrial cancer.
    Mutlu L; Harold J; Tymon-Rosario J; Santin AD
    Expert Rev Anticancer Ther; 2022 Mar; 22(3):249-258. PubMed ID: 35176955
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase 2 evaluation of pembrolizumab for recurrent Lynch-like versus sporadic endometrial cancers with microsatellite instability.
    Bellone S; Roque DM; Siegel ER; Buza N; Hui P; Bonazzoli E; Guglielmi A; Zammataro L; Nagarkatti N; Zaidi S; Lee J; Silasi DA; Huang GS; Andikyan V; Damast S; Clark M; Azodi M; Schwartz PE; Tymon-Rosario JR; Harold JA; Mauricio D; Zeybek B; Menderes G; Altwerger G; Ratner E; Alexandrov LB; Iwasaki A; Kong Y; Song E; Dong W; Elvin JA; Choi J; Santin AD
    Cancer; 2022 Mar; 128(6):1206-1218. PubMed ID: 34875107
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Polymerase ε (POLE) ultra-mutation in uterine tumors correlates with T lymphocyte infiltration and increased resistance to platinum-based chemotherapy in vitro.
    Bellone S; Bignotti E; Lonardi S; Ferrari F; Centritto F; Masserdotti A; Pettinella F; Black J; Menderes G; Altwerger G; Hui P; Lopez S; de Haydu C; Bonazzoli E; Predolini F; Zammataro L; Cocco E; Ferrari F; Ravaggi A; Romani C; Facchetti F; Sartori E; Odicino FE; Silasi DA; Litkouhi B; Ratner E; Azodi M; Schwartz PE; Santin AD
    Gynecol Oncol; 2017 Jan; 144(1):146-152. PubMed ID: 27894751
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeted Treatment of Advanced Endometrial Cancer: Focus on Pembrolizumab.
    El-Ghazzi N; Durando X; Giro A; Herrmann T
    Onco Targets Ther; 2023; 16():359-369. PubMed ID: 37288137
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of Benefit from Checkpoint Inhibitors in Mismatch Repair Deficient Metastatic Colorectal Cancer: Role of Tumor Infiltrating Lymphocytes.
    Loupakis F; Depetris I; Biason P; Intini R; Prete AA; Leone F; Lombardi P; Filippi R; Spallanzani A; Cascinu S; Bonetti LR; Maddalena G; Valeri N; Sottoriva A; Zapata L; Salmaso R; Munari G; Rugge M; Dei Tos AP; Golovato J; Sanborn JZ; Nguyen A; Schirripa M; Zagonel V; Lonardi S; Fassan M
    Oncologist; 2020 Jun; 25(6):481-487. PubMed ID: 31967692
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immune Checkpoint Inhibitors in Gynecological Cancers: Update of Literature and Perspectives of Clinical Research.
    Gadducci A; Guerrieri ME
    Anticancer Res; 2017 Nov; 37(11):5955-5965. PubMed ID: 29061774
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Endometrial Tumors with MSI-H and dMMR Share a Similar Tumor Immune Microenvironment.
    Song Y; Gu Y; Hu X; Wang M; He Q; Li Y
    Onco Targets Ther; 2021; 14():4485-4497. PubMed ID: 34429613
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Microsatellite instability is a biomarker for immune checkpoint inhibitors in endometrial cancer.
    Yamashita H; Nakayama K; Ishikawa M; Nakamura K; Ishibashi T; Sanuki K; Ono R; Sasamori H; Minamoto T; Iida K; Sultana R; Ishikawa N; Kyo S
    Oncotarget; 2018 Jan; 9(5):5652-5664. PubMed ID: 29464025
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Endometrial Carcinoma: Immune Microenvironment and Emerging Treatments in Immuno-Oncology.
    Rousset-Rouviere S; Rochigneux P; Chrétien AS; Fattori S; Gorvel L; Provansal M; Lambaudie E; Olive D; Sabatier R
    Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34199461
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New therapeutic targets for endometrial cancer: a glimpse into the preclinical sphere.
    Bruchim I; Capasso I; Polonsky A; Meisel S; Salutari V; Werner H; Lorusso D; Scambia G; Fanfani F
    Expert Opin Ther Targets; 2024; 28(1-2):29-43. PubMed ID: 38327111
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Mismatch repair deficiency, next-generation sequencing-based microsatellite instability, and tumor mutational burden as predictive biomarkers for immune checkpoint inhibitor effectiveness in frontline treatment of advanced stage endometrial cancer.
    Hill BL; Graf RP; Shah K; Danziger N; Lin DI; Quintanilha J; Li G; Haberberger J; Ross JS; Santin AD; Slomovitz B; Elvin JA; Eskander RN
    Int J Gynecol Cancer; 2023 Apr; 33(4):504-513. PubMed ID: 36750267
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The role of immunotherapy in advanced and recurrent MMR deficient and proficient endometrial carcinoma.
    Di Dio C; Bogani G; Di Donato V; Cuccu I; Muzii L; Musacchio L; Scambia G; Lorusso D
    Gynecol Oncol; 2023 Feb; 169():27-33. PubMed ID: 36493574
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Tumor immune microenvironment in endometrial cancer of different molecular subtypes: evidence from a retrospective observational study.
    Dai Y; Zhao L; Hua D; Cui L; Zhang X; Kang N; Qu L; Li L; Li H; Shen D; Wang Z; Wang J
    Front Immunol; 2022; 13():1035616. PubMed ID: 36532042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 22.